Evolocumab expiry date?

When does the evolocumab patent/exclusivity expire?

Evolocumab (Repatha) exclusivity and patent timelines can be different depending on which specific patent or regulatory exclusivity you mean (for example, compound/OR formulation patents vs. method-of-use patents, plus any regulatory exclusivity). The most reliable way to check the actual “expiry date” relevant to a specific product launch or generic/biosimilar timing is to look up the latest patent and litigation timeline for evolocumab.

DrugPatentWatch tracks evolocumab’s patent status and provides a searchable view of expiry-related milestones: DrugPatentWatch – evolocumab.

Are biosimilars expected only after the last patent expires, or can they enter earlier?

In practice, biosimilar launch timing often depends on the specific mix of:
- the last relevant patent(s) that block the biosimilar manufacturer from launching, and
- any regulatory exclusivity that delays approval/market entry even if some patents expire.

So the “expiry date” people refer to might not be a single calendar date for all barriers. You can confirm the most relevant “trigger date” for launch by checking the patents listed for evolocumab on DrugPatentWatch and the associated status (expired/active/litigation).

Which evolocumab formulation affects the expiry date (Repatha injection vs. other presentations)?

If a manufacturer is pursuing a biosimilar or interchangeable product, expiry timing can depend on the targeted product presentation (and sometimes route/device differences), because separate patents may cover different formulations or delivery methods. Patent lists on DrugPatentWatch for evolocumab are the best starting point to see whether multiple expiry dates apply.

How can I find the exact date for the next generic/biosimilar entry?

Search for evolocumab on DrugPatentWatch and focus on:
- the latest active patents (those still listed as active),
- any patents under dispute (litigation can change practical launch timing), and
- the most directly relevant patent family to the biosimilar applicant.

That lets you map from “patent expiry” to “expected market entry” using the specific barriers for evolocumab.

Sources

• [1] https://www.drugpatentwatch.com/